We're #hiring a new Senior Distribution Manager in United States. Apply today or share this post with your network.
Summit Therapeutics, Inc.
生物技术研究
Miami，Florida 16,576 位关注者
Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health.
关于我们
Summit Mission Statement: To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate. We accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position. Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders. Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK.
- 网站
-
https://www.smmttx.com/
Summit Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Miami，Florida
- 类型
- 上市公司
- 创立
- 2003
- 领域
- Oncology、Clinical Trials和Health Care
地点
Summit Therapeutics, Inc.员工
动态
-
Summit is excited to officially kick-off #ESMO24 In Barcelona Spain, September 9th-13th. We invite you to stop by our Summit Medical Affairs booth #A431. You can also meet Dr. Jack West during the dedicated times listed below. Our team looks forward to meeting you! For information on ivonescimab publications: *Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). #SMMTNewEra #Ivonescimab #oncology?
-
-
Summit is honored to announce three ivonescimab posters, two are mini-oral presentations during #ESMO24 which is being held in Barcelona Spain, September 9th-13th! The indications in these trials sponsored by Akeso, Summit’s partner, include triple-negative breast, head, and neck squamous cell carcinoma and recurrent/metastasis head and neck squamous cell carcinoma. Please refer to the list below for more details. For information on ivonescimab publications: https://lnkd.in/euGQe4zP We invite you to stop by our Summit Medical Affairs booth #A431. Our team looks forward to meeting you! *Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). #SMMTNewEra #Ivonescimab #oncology
-
-
We're #hiring a new Corporate Counsel (Hybrid) in Menlo Park, California. Apply today or share this post with your network.
-
Summit Therapeutics Raises $235 Million Full Press Release Here:https://lnkd.in/dWKPX7yT #SMMTNewEra #Ivonescimab ##lungcancer #oncology
-
-
Congratulations Bob Duggan and Maky Zanganeh, our co-CEOs, on your CNBC interview today! *Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). #ivonescimab #SMMT #SMMTNewEra #lungcancer #oncology
-
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with?PD-L1 Positive Advanced NSCLC in China Full Press Release Here: https://lnkd.in/gAvUNM_N #SummitTherapeutics #oncology #WCLC24 #IASLC #Ivonescimab
-
-
We are back from the?WCLC 24 Presidential Symposium: Primary analysis of the Phase III HARMONi-2 trial conducted by Akeso in China, featuring its novel, potential first-in-class investigational bispecific antibody, ivonescimab. Presented: Sunday, September 8, 2024, PL02.04 Please stop by and see us! We look forward to having you visit Summit Medical Affairs Booth #2900- Team Summit (Follow us for more updates!) *Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). #SMMTNewEra #WCLC24 #Ivonescimab #HARMONi-2 #IASLC50 #lungcancer #oncology
-
-
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with?PD-L1 Positive Advanced NSCLC in China Full Press Release Here: https://lnkd.in/gAvUNM_N #SummitTherapeutics #oncology #WCLC24 #IASLC #Ivonescimab
-
-
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with?PD-L1 Positive Advanced NSCLC in China Full Press Release Here: https://lnkd.in/gAvUNM_N #SummitTherapeutics #oncology #WCLC24 #IASLC #Ivonescimab
-